Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Current assets:
Cash, cash equivalents and restricted cash	$ 110,891,000	$ 108,005,000
Accounts receivable	0	1,410,000
Available-for-sale securities, at fair value	292,735,000	0
Held-to-maturity securities, at amortized cost	0	268,391,000
Prepaid expenses	8,813,000	7,289,000
Other current assets	7,082,000	20,204,000
Total current assets	419,521,000	405,299,000
Property and equipment, net	290,262,000	110,297,000
Intangible assets, net	10,262,000	11,962,000
Held-to-maturity securities, at amortized cost	0	105,872,000
Right-of-use assets	45,297,000	58,291,000
Other assets	210,000	218,000
Total Assets	765,552,000	691,939,000
Current liabilities:
Accounts payable	35,866,000	2,868,000
Accrued expenses	39,763,000	46,856,000
Accrued payroll and benefits	17,963,000	12,251,000
Lease liabilities	10,563,000	2,776,000
Deferred revenue	866,000	74,099,000
Other liabilities	435,000	0
Total current liabilities	105,456,000	138,850,000
Long-term liabilities:
Lease liabilities, net of current portion	104,608,000	78,800,000
Deferred revenue, net of current portion	0	55,950,000
Liability related to the sale of future royalties	268,326,000	0
Total long-term liabilities	372,934,000	134,750,000
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders' equity:
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,312 and 105,960 shares	200,000	198,000
Additional paid-in capital	1,300,395,000	1,219,213,000
Accumulated other comprehensive loss	(3,222,000)	(136,000)
Accumulated deficit	(1,026,030,000)	(820,755,000)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	271,343,000	398,520,000
Noncontrolling interest	15,819,000	19,819,000
Total noncontrolling interest and stockholders' equity	287,162,000	418,339,000
Total Liabilities, Noncontrolling Interest and Stockholders' Equity	$ 765,552,000	$ 691,939,000